Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function
https://doi.org/10.18087/cardio.2021.10.n1767
Abstract
This review focuses on issues of anticoagulant therapy in patients with atrial fibrillation (AF) associated with chronic kidney disease (CKD). Such patients are at high risk of stroke whereas the choice of an anticoagulant is difficult. A wealth of information about a negative effect of warfarin on the kidney function has accumulated. A need for an alternative therapy to warfarin for patients with stage 3-4 CKD has become imminent. In this regard, rivaroxaban seems to be an appropriate replacement for warfarin in such patients. In randomized, controlled studies that evaluated the efficacy of direct oral anticoagulants in comparison with warfarin, the efficacy and safety profile of a “kidney” dose in moderate disorders of kidney function has been studied only for rivaroxaban. Moreover, both randomized, controlled studies and studies performed in the conditions of clinical practice, have demonstrated a more favorable effect of rivaroxaban on kidney function compared to warfarin. Patients with AF associated with CKD require a comprehensive protection, which, according to results of clinical studies, may be provided by rivaroxaban.
Supporting agencies: The publication was supported by AO “BAYER”, 10.2021 (PP-XAR-RU-0834-1).
About the Author
T. N. Novikova
I.I. Mechnikov North-Western State Medical University, Saint Petersburg
Russian Federation
Russian Federation
Associate Professor of the Department of Hospital Therapy and Cardiology named after M.S. Kushakovsky
References
1. Ding WY, Gupta D, Wong CF, Lip GYH. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovascular Research. 2021;117(4):1046–59. DOI: 10.1093/cvr/cvaa258
2. Park S, Lee S, Kim Y, Lee Y, Kang MW, Kim K et al. Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study. European Heart Journal. 2021;ehab291. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehab291
3. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). American Heart Journal. 2010;159(6):1102–7. DOI: 10.1016/j.ahj.2010.03.027
4. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2020;22(4):584–603. DOI: 10.1002/ejhf.1697
5. Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nature Reviews Nephrology. 2018;14(5):337–51. DOI: 10.1038/nrneph.2018.19
6. Novikova T.N., Ashurov A.B., Kiseleva M.V., Plotnikova M.O., Podoprigora E.A., Sayganov S.A. et al. Stroke Prevention in Patients with Atrial Fibrillation in Real Clinical Practice, Emphasis on Efficacy and Safety of Anticoagulant Therapy. Kardiologiia. 2020;60(4):54–61. DOI: 10.18087/cardio.2020.4.n1023
7. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612
8. Ministry of Health of Russian Federation. Clinical recommendations: Atrial fibrillation and flutter in adults. (CR382). 2020. https://cr.minzdrav.gov.ru/recomend/382_1]
9. Belenkov Yu.N., Shakaryants G.A., Khabarova N.V., An G.V. Anticoagulant Therapy in Elderly Patients With Atrial Fibrillation. Kardiologiia. 2018;58(10):45–52. DOI: 10.18087/cardio.2018.10.10177
10. Heine GH, Brandenburg V, Schirmer SH. Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. Deutsches Aerzteblatt Online. 2018;115(17):287–94. DOI: 10.3238/arztebl.2018.0287
11. Arnson Y, Hoshen M, Berliner-Sendrey A, Reges O, Balicer R, Leibowitz M et al. Risk of Stroke, Bleeding, and Death in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease. Cardiology. 2020;145(3):178–86. DOI: 10.1159/000504877
12. Sy J, Hsiung J-T, Edgett D, Kalantar-Zadeh K, Streja E, Lau WL. Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. American Journal of Nephrology. 2021;52(3):199–208. DOI: 10.1159/000514753
13. van Gorp R, Schurgers L. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients. 2015;7(11):9538–57. DOI: 10.3390/nu7115479
14. Obrezan A.G., Zemchenkov A.Yu. Chronic Kidney Disease as Basis of High Thrombotic and Bleeding Risk in Patients With Atrial Fibrillation: Place of Oral Anticoagulants. Kardiologiia. 2018;58(4):60–70. DOI: 10.18087/cardio.2018.4.10111
15. Brodsky SV, Satoskar A, Chen J, Nadasdy G, Eagen JW, Hamirani M et al. Acute Kidney Injury During Warfarin Therapy Associated With Obstructive Tubular Red Blood Cell Casts: A Report of 9 Cases. American Journal of Kidney Diseases. 2009;54(6):1121–6. DOI: 10.1053/j.ajkd.2009.04.024
16. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney International. 2011;80(2):181–9. DOI: 10.1038/ki.2011.44
17. Galloway PAG, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK et al. Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease. Nephron. 2015;129(3):197–201. DOI: 10.1159/000371449
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361(12):1139–51. DOI: 10.1056/NEJMoa0905561
19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638
20. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039
21. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. The Lancet. 2012;380(9855):1749–58. DOI: 10.1016/S0140-6736(12)60986-6
22. Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. Journal of the American College of Cardiology. 2013;62(10):900–8. DOI: 10.1016/j.jacc.2013.05.042
23. Martsevich S.Yu., Navasardian A.R., Zakharova N.A., Lukianov М.М. New oral anticoagulants: is that plausible to implement the data from international trials to Russian population? Cardiovascular Therapy and Prevention. 2015;14(5):48–52.
24. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI: 10.1093/eurheartj/ehr342
25. Chashkina M.I., Andreev D.A., Kozlovskaya N.L., Salpagarova Z.K., Suvorov A.Yu., Suchkova S.A. et al. Safety performance of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Kardiologiia. 2020;60(11):94–100. DOI: 10.18087/cardio.2020.11.n1322
26. Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA et al. Renal Outcomes in Anticoagulated Patients with Atrial Fibrillation. Journal of the American College of Cardiology. 2017;70(21):2621–32. DOI: 10.1016/j.jacc.2017.09.1087
27. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;74(1):104–32. DOI: 10.1016/j.jacc.2019.01.011
28. Bonnemeier H, Huelsebeck M, Kloss S. Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany – A retrospective cohort study. International Journal of Cardiology. Heart & Vasculature. 2019;23:100367. DOI: 10.1016/j.ijcha.2019.100367
29. Chen H-Y, Ou S-H, Huang C-W, Lee P-T, Chou K-J, Lin P-C et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clinical Drug Investigation. 2021;41(4):341–51. DOI: 10.1007/s40261-021-01016-7
30. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021;euab065. [Epub ahead of print]. DOI: 10.1093/europace/euab065
31. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. British Journal of Clinical Pharmacology. 2010;70(5):703–12. DOI: 10.1111/j.1365-2125.2010.03753.x
32. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen-2012-001592
Review
For citations:
Novikova T.N. Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function. Kardiologiia. 2021;61(10):81-88. (In Russ.) https://doi.org/10.18087/cardio.2021.10.n1767
Views:
1055
Email this article 
Post a Comment 
